Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ilaria Marcelli
Observed names:
I Marcelli,
I. Marcelli,
Marcelli, Ilaria
Institution:
Università Cattolica del Sacro Cuore
Observed institutions:
Università Cattolica del Sacro Cuore,
Baylor College of Medicine,
Agostino Gemelli University Polyclinic
ORCID:
0009-0001-6252-2600
Observed ORCID:
0009-0001-6252-2600
OpenAlex ID:
A5014589273
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
2023
·
Maria Pepe
, Giovanni Bartolucci
, et al.
·
Brain Sciences
·
28
PDF
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)
2025
·
Marco Di Nicola
, Maria Pepe
, et al.
·
Journal of Personalized Medicine
·
24
PDF
Childhood sexual abuse and suicide attempts in patients with substance use disorders: The mediating role of emotion dysregulation
2024
·
Marco Di Nicola
, Maria Pepe
, et al.
·
Child Abuse & Neglect
·
15
Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series
2023
·
Maria Pepe
, Giovanni Bartolucci
, et al.
·
Journal of Psychiatric Practice
·
14
This pain drives me crazy: Psychiatric symptoms in women with interstitial cystitis/bladder pain syndrome
2024
·
Marianna Mazza
, Stella Margoni
, et al.
·
World Journal of Psychiatry
·
12
PDF
Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report
2024
·
Lorenzo Moccia
, Giovanni Bartolucci
, et al.
·
Journal of Clinical Medicine
·
9
PDF
Childhood trauma assessed using the childhood trauma questionnaire and its influence on pediatric mood disorders and self-harm: a systematic review and meta-analysis
2026
·
Silvia Montanari
, Tommaso Callovini
, et al.
·
Child Abuse & Neglect
·
2
Extended-Release Trazodone in Comorbid Major Depressive and Sedative–Hypnotic/Anxiolytic Use Disorders: A Real-World Preliminary Evaluation of Multidimensional Outcomes
2026
·
Marco Di Nicola
, Maria Pepe
, et al.
·
Journal of Clinical Medicine
Evaluating seltorexant as a treatment option for major depressive disorder
2026
·
Marco Di Nicola
, Maria Pepe
, et al.
·
Expert Review of Neurotherapeutics
PDF
The association between anhedonia and quality of life in treatment-resistant depression: effects of a three-month treatment with esketamine nasal spray
2026
·
I. Marcelli
, M. Pepe
, et al.
·
European Psychiatry
PDF
Gut microbiota in major depressive disorder and treatment-resistant depression before and after intranasal esketamine treatment: a pilot study
2026
·
A.M. D'Onofrio
, G.F. Ferrajoli
, et al.
·
Neuroscience Applied
PDF
Pharmacological treatment of psychiatric symptoms in Huntington’s disease: a systematic review
2026
·
T. Callovini
, S. Montanari
, et al.
·
Neuroscience Applied
189. Exploring the Subjective Experience of Patients With Treatment-resistant Depression on the Effects of Esketamine Nasal Spray
2025
·
M Pepe
, I Marcelli
, et al.
·
The International Journal of Neuropsychopharmacology
PDF
Self-harm and personality domains: a useful lens for mood disorders characterization in young-adults
2024
·
S. Montanari
, G. Bartolucci
, et al.
·
Neuroscience Applied
Exploring heart rate variability as a possible predictor of response to intranasal esketamine in individuals with treatment-resistant depression
2024
·
G. Bartolucci
, L. Moccia
, et al.
·
Neuroscience Applied
The effect of intranasal esketamine on key domains of treatment-resistant depression: clinicians and patients’ perspective
2023
·
M. Pepe
, G. Bartolucci
, et al.
·
Neuroscience Applied
Show more works
View as search
Works count:
19
Citation count:
125
H-index:
7
I10-index:
6
Year
Topic
Type